Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- +4 vs. Q3 2024
- Shares held
- 25.9M
- +11.4M (+78.6%) vs. Q3 2024
- Total value
- $24.7M
- +$13.3M (+116.3%) vs. Q3 2024
- New holders
- 9
- 6 more added
- Sold out
- 5
- 6 more reduced
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 9,105,451 | $8.70M | 0.56% | +9,105,451 | New |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $4.36M | 0.51% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 3,003,259 | $2.87M | 0.11% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $1.42M | 0.55% | +1,483,758 | New |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.42M | 5.33% | 00.0% | Unchanged |
| FMR LLC | 1,395,853 | $1.33M | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,001,359 | $956.3K | 0.00% | −520,743−34.2% | Reduced |
| Vanguard Group Inc | 902,531 | $861.9K | 0.00% | 00.0% | Unchanged |
| AJU IB Investment Co., Ltd. | 667,742 | $637.7K | 0.62% | +667,742 | New |
| Geode Capital Management, LLC | 358,422 | $342.3K | 0.00% | +20,230+6.0% | Added |
| Balyasny Asset Management LLC | 343,230 | $327.8K | 0.00% | +70,744+26.0% | Added |
| Renaissance Technologies LLC | 296,617 | $283.3K | 0.00% | +30,317+11.4% | Added |
| Trustees of Columbia University in the City of New York | 249,635 | $238.4K | 0.04% | +249,635 | New |
| UBS Group AG | 249,401 | $238.2K | 0.00% | +233,668+1,485.2% | Added |
| FIL Ltd | 218,705 | $208.9K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 76,086 | $72.7K | 0.00% | +462+0.6% | Added |
| Bridgeway Capital Management, LLC | 71,081 | $67.9K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 50,086 | $47.8K | 0.00% | +50,086 | New |
| Susquehanna International Group, LLP | 49,093 | $46.9K | 0.00% | +49,093 | New |
| State Street Corp | 43,390 | $41.4K | 0.00% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 41,000 | $39.2K | 0.00% | +41,000 | New |
| Citadel Advisors LLC | 40,316 | $38.5K | 0.00% | +40,316 | New |
| Northern Trust Corp | 39,208 | $37.4K | 0.00% | 00.0% | Unchanged |
| SevenBridge Financial Group, LLC | 41,000 | $26.9K | 0.01% | 00.0% | Unchanged |
| Mariner, LLC | 25,000 | $23.9K | 0.00% | −317−1.3% | Reduced |
| Steward Partners Investment Advisory, LLC | 20,000 | $19.1K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 12,870 | $12.3K | 0.00% | −10,992−46.1% | Reduced |
| Two Sigma Investments, LP | 10,824 | $10.3K | 0.00% | +435+4.2% | Added |
| Pinnacle Financial Group, LLC | 10,000 | $9.55K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 3,300 | $3.15K | 0.00% | +3,300 | New |
| Tower Research Capital LLC (TRC) | 2,729 | $2.61K | 0.00% | −2,887−51.4% | Reduced |
| Key Financial Inc | 830 | $793 | 0.00% | 00.0% | Unchanged |
| Private Wealth Management Group, LLC | 310 | $297 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 265 | $253 | 0.00% | −1−0.4% | Reduced |
| JPMorgan Chase & Co | 66 | $63 | 0.00% | −9−12.0% | Reduced |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −44,445−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −32,752−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −20,655−100.0% | Sold out |
| Avantax Planning Partners, Inc. | 0 | $0 | 0.00% | −20,483−100.0% | Sold out |
| Dunhill Financial, LLC | 0 | $0 | 0.00% | −10,274−100.0% | Sold out |
| RiverVest Venture Management LLC | – | – | – | – | Not filed |
| Raymond James & Associates | – | – | – | – | Not filed |